The game changer: UCH-L1 and GFAP-based plasma test as the first marketed in vitro diagnostic test for mild traumatic brain injury.

The introduction of the i-STAT Alinity™ and the Biomerieux Vidas TBI blood tests mark a groundbreaking development in the field of TBI diagnosis. It paves the way for the integration of TBI biomarker tools into clinical practice and therapeutic trials, enhancing the precision medicine approach by generating valuable data. This advancement is a critical step in addressing the long-standing gap in brain-related diagnostics and promises to revolutionize the management and treatment of mild TBI.